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Multiple Sclerosis, Physical Therapy, and Quality of Life Insights 
By Claire Simon 
 
Introduction 
Multiple sclerosis (MS) is a progressive neurological disease with no known cure. 
Current medications and therapies can only treat symptoms and slow disease onset, 
but they cannot reverse the permanent brain damage.   
 MS is caused by brain damage induced by constant attacks from the immune 
system on neurons. Specifically, T-cells, cytokines, and other molecules from immune 
and inflammatory responses damage the myelin, which is the fatty layer surrounding the 
neuronal axis that helps propagate an action potential [1]. Myelin degradation thereby 
slows action potentials, prevents electrical signal transduction, and effectively 
suppresses communication between the brain and spinal cord [2]. This leads to the 
most notable MS symptoms of mobility impairment, muscle weakness, spasticity, 
urinary and bowel incontinence, and chronic pain [3]. The immune and inflammatory 
response molecules also damage myelin repair cells known as oligodendrocytes, which 
prevents myelin sheath repair and leads to the progressive nature of neuronal loss that 
can be viewed in an MRI as brain lesions [4]. Other symptoms of MS include 
depression, chronic fatigue, and anxiety [1]. 
 MS is also characterized by symptom relapse and remittance that falls into three 
distinct pathologies. The most prevalent type of MS, termed relapsing remitting, 
constitutes 85% of MS diagnoses and is defined by periods of relapse (worsening 
inflammatory processes that last longer than 24 hours) and remittance (periods of little 
to no symptoms) [1, 4]. Over time, these episodes of relapse get progressively more 
frequent, intense, and lengthy corresponding to the disease progression and brain 
damage [1]. In primary progressive MS, symptoms continue to worsen without periods 
of remission and may have plateaus; this affects ~10% of MS patients and is the type 
generally less responsive to drug treatments [1]. The third type, secondary progressive, 
usually develops from relapsing remitting and is a continuous state of worsening 
disease progress with or without remittance. Finally, the rarest form of MS (less than 
5%) is essentially a more intense version of primary progressive where disease 
progressively worsens faster with occasional flare-ups and fewer plateau incidents [1]. 
Although there is no known direct cause, trends of MS diagnosis suggest genetic 
contributions along with non-genetic factors, such as the environment, viral infections, 
and metabolism [1]. The most common diagnosed case of MS occurs in women from 
20-40 years old of Northern European descent, who are twice as likely to have MS than 
men [1, 5]. Another study using a MS patient database found peoples of African 
ancestry conferred more risk for secondary progressive MS in age of onset and number 
of relapses [6]. While the cause of MS is not yet clear, genetic studies are facing 
challenges in an attempt to find specific alleles and causative genes and continue to 
find a causative link between MS, genes, and the environment [7]. 
While a cure for MS remains elusive, there are several treatment options that are 
mainly disease modifying. The MS demyelination mechanism cannot yet be reversed by 
drug therapies, but interferon-ß (IFN) is the primary disease-modifying drug therapy 
since 1994 and is used in multiple prescribed medications [1, 8]. IFN formulates 
neutralizing antibodies and reduces the efficacy of disease progression [8]. Early 
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diagnosis is useful for IFN medical treatment since the medication is beneficial when 
administered at the time of the first and early relapse periods, halting disease 
progression as early as possible [4, 5]. 
Other MS treatments ranging from mental to physical therapies target symptoms 
such as depression, cognitive decline, fatigue, bladder incontinence, and spasticity. 
Behavioral learning therapies may be effective in preventing certain aspects of cognitive 
decline [9], and antidepressants and exercise protocols are being examined to combat 
MS fatigue [3,10]. An analysis of four qualified studies found that alternative treatment 
options such as mindfulness, yoga, biofeedback, and relaxation techniques positively 
affect depression, anxiety, quality of life (QoL), and fatigue [11]. Even smoked cannabis 
has been shown to reduce pain and treatment-resistant muscle spasticity in a trial of 30 
patients [12]. 
Physical therapy (PT) offers profound benefits to patients with MS in alleviating 
adverse side effects and improving QoL. PT improves muscle strength, flexibility, and 
mobility training for daily life activities. Even small improvements in fatigue from 
exercise protocols [3], and improvements in bladder incontinence from pelvic floor 
exercises directly contribute to an improved QoL from symptom reduction [13]. A 
consistent PT treatment may also reduce forms of disability in patients suffering from 
muscle weakness and coordination loss [14]. 
After learning of the prevalence of MS in young women and gaining an interest in 
the neuropathology and treatment of the disease, I sought to gain perspective of this 
disease through observing on-site MS clinical PT sessions at my university and 
interviewing MS patients.  After shadowing the clinic, interviewing three MS patients, 
and administering a standard QoL assessment test, I found support for the unique 
benefits of PT for treating disease and improving QoL. 
 
Materials and Methods 
Clinical Observation 
The University of Puget Sound PT clinic is a relatively free service of physical and 
occupational therapies that is run by graduate student therapists under the supervision 
of professional and experienced instructors. During my internship, I shadowed a 
physical therapist and observed various PT sessions in the UPS PT clinic for three days 
(total of six hours). During my observations, I was instructed on clinical techniques in 
treating various neurological diseases, including MS, and reviewed clinical charts and 
treatment histories of MS patients. 
Quality of Life Assessment and Patient Interview 
With written permission, I interviewed three patients with different types and stages of 
MS (Table 1). I asked several questions pertaining to their personal experiences with 
the disease, treatment histories, and perspectives on various received treatments, with 
a focus on PT. 
In addition to the interview, I administered a Schedule for the Evaluation of 
Individual Quality of Life Direct Weighting (SEIQoL-DW) procedure as described by 
O’Boyle and colleagues [15]. I asked the five areas (“Cues”) that contributed to the 
patients’ happiness and QoL and asked them to rate how important each cue was 
relative to the others (Weight) by assigning each cue a percent out of the total 100% on 
a pie chart. I then asked each patient to rate the level of satisfaction with each 
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respective cue at the current moment in his or her life by drawing a representative bar 
graph (“Level”) to indicate a score of satisfaction. The height of the bar in millimeters 
corresponded to a score out of 100 (Fig. 1).  All interviews were recorded for later 
analysis (Supplemental Interviews available upon request). 
Literature Research 
To compliment my observations and experiments, I conducted a preliminary literature 
research on current medications, treatment options, and neuropathology theories 
(presented mainly in the Introduction) using a variety of search engines (e.g. Google 
Scholar, UPS Collins Memorial Library, and PubMed). 
 
Results and Discussion 
Table 1. Patient Interviewee Profiles 
Patient Gender Age (years) 
Age of 
Diagnosis 
(years) 
Disease Type Mobility Profile 
1 Female 54 29 Primary Progressive Wheelchair 
2 Female 64 44 Secondary Progressive 
Limited 
walking with 
cane 
assistance 
3 Male 55 37 Secondary Progressive Wheelchair 
 
Each patient was cognitively able and engaged in SEIQoL-DW procedure, which 
took an average of 15 minutes each to complete. Some patients were more responsive 
to the interview portion than others, but each session was informative and lasted one 
hour at maximum.  In administering a standard QoL procedure I was able to quantify my 
results and have the ability to compare with other studies using the same measurement. 
A study by Hickey and colleagues [16], for example, uses the SEIQoL-DW to measure 
QoL in HIV/AIDS and drug users and could be used as a reference point for the QoL 
outcome by similar symptoms in MS.  
The SEIQoL-DW procedure was chosen based on literature support as the most 
appropriate standard for general QoL analysis. In general, this type of protocol is 
focused on an individual frame of reference for QoL analysis, and the SEIQoL-DW 
(when compared to other QoL protocols) specifically focuses on intrinsic feelings of 
health and vitality, as opposed to physical ability or other aspects of a disease [17]. 
However, there are notable limitations in this analysis since a small sample size was 
used and patient self-ratings may come with a variety of biases, including a reflection of 
coping strategies (i.e. staying positive) [17]. Yet for my purposes, this procedure was 
beneficial and advantageous in general QoL analysis. 
As a general trend, all patients listed a version of social support among their cues 
and with the most weight in QoL (Fig.1).  Patient 2 applied more weight for self-reliance 
than did others and Patient 3 was the only one that mentioned any spirituality or religion 
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(Fig. 1). Notably, none of the patients explicitly referenced health as a factor for QoL, 
although it can be argued that health is implied in categories such as self-reliance and 
independence. 
 
The common cues that contribute to QoL in patients seem to provide emotional 
support, which makes sense given the nature of the disease and the fears mentioned in 
the interview. According to Patient 1, “[MS] just continued to get worse and worse. And 
that is really depressing—being able to do less and less.” Patient 2 said, “I think the 
unknown and not knowing what’s going to happen…in the future is kind of scary.” In 
light of these fears, positivity, staying active, and having healthy, supportive 
relationships is intuitively crucial to QoL with MS. 
In agreement with the literature, patient interviews revealed the fundamental 
benefits of PT in QoL.  All three patients agreed that PT provides a goal and source of 
motivation that acts as a “vital tool” for a healthy mental and physical state.  The 
motivation they spoke of gets them out of the house, which benefits familial caregivers 
by providing a break and adds a sense of independence and daily activity to the 
patient’s life, an important factor in self-rated QoL (Fig. 1).  PT is also very interactive, 
as it requires communication on the part of both the therapist and patient and requires 
physical participation from the patient. This not only initiates a social relationship but 
also instills a feeling of control and self-confidence in the patient.  A patient is actively 
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participating, meeting goals, and taking action to improve their health situation, which 
may help stave off anxiety, depression, and passive, pessimistic feelings known to 
persist when one has a perceived loss of control [10]. One patient reports on the mental 
and social benefit of PT, “…your mental state will be better because when you have to 
think and you have to work you’re causing your mind to work…I enjoy working with the 
student [therapists].” As I observed in the clinic, student therapists not only focused on 
symptom improvement and muscle strengthening but also tailored treatments specific to 
the patients’ requests and encouraged mental strength by establishing goals, assigning 
home exercises, and explicitly calling attention to and praising improvements. 
A sense of control and active physical and mental participation is notably unique 
to PT in comparison to drug therapy. According to patients, benefits of medicine are 
less apparent, which often leads to frustration: “I’m not even sure [medications] are 
doing anything. I take them mostly to keep [symptoms] from progressing,” “[PT] so 
improves the quality of my life…Medication is just keeping things from getting worse, 
but it’s not like I really know what it’s doing,” and “…when I started getting worse—my 
walking [and] fatigue got worse—the medicine just didn’t seem to be helping.” Because 
medicine can’t reverse brain damage and the effects of MS, it can often be frustrating to 
patients with false expectations or unfounded optimism.  While medicine is 
physiologically important to sustain health and slow disease progress, PT seems to 
foster beneficial optimism and improve symptoms such as muscle strength that may 
directly apply to daily life activities.  The mental well-being and sustained QoL offered by 
PT is crucial for one who must live with the mental and physical anguish of an incurable 
disease. 
The UPS PT clinic was particularly unique and benefitted both patients and 
student therapists. Patients benefit from nearly nonexistent fees, unique attention (often 
by one or more therapists at one time), student enthusiasm, and creative therapy 
techniques.  For some of the interviewed patients, a majority of PT progress was lost 
after insurance coverage expired. The UPS clinic helped continue much needed PT 
treatment for those without insurance. Student therapists benefit from the clinic because 
of the access to hands-on, professional, and rewarding experience in PT. 
In conducting my interviews, many other questions arose for future research and 
discussion.  For one, patient access to research and MS news was limited to 
magazines, newsletters from local or national MS community chapters, public websites, 
and pamphlets released by drug companies.  Biased drug information provided by 
companies may instill false expectations of medicine and contribute to a sense of 
frustration in patients. For example, one patient became discouraged after taking a drug 
she read about called “The Walking Cure” when it failed to work with her disease. The 
dramatic name may look good for a drug company, but it instilled a sense of false 
optimism in a patient struggling with MS. Additionally, I would like to research and 
discuss regulations for age of MS diagnosis and potential drug therapies that attempt to 
repair myelin damage instead of simply preventing it. 
In conducting this neuroscience internship, I gained first-hand experience with 
personal aspects of MS and a PT treatment option. This offered me several 
perspectives into a complex neurological condition ranging from molecular pathology to 
personal human struggle that doubles as invaluable insight in pursuing a career in 
neuroscience. 
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